Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways

NCT07146503 is registered in ClinicalTrials.gov with Riccardo Guglielmo as lead sponsor.

NCT NCT07146503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07146503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways
Lead sponsor
Riccardo Guglielmo
Phase
Observational
Overall status
Recruiting
Start date
November 1, 2022
Completion date
August 31, 2030
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anhedonia, anxiety, apathy, cognition, depression and quality of life, psychiatric comorbidities, temperament, treatment resistant depression (trd)